tiprankstipranks
Imugene Limited (AU:IMU)
ASX:IMU

Imugene Limited (IMU) Share Price & Analysis

26 Followers

IMU Stock Chart & Stats

Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.04 - AU$0.15
Previous CloseAU$0.11
Volume1.93M
Average Volume (3M)13.58M
Market Cap
AU$768.43M
Enterprise ValueAU$669.21M
Total Cash (Recent Filing)AU$99.89M
Total Debt (Recent Filing)AU$673.43K
Price to Earnings (P/E)-8.0
Beta1.54
Aug 30, 2024
-AU$0.01
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding7,318,369,771
10 Day Avg. Volume34,707,258
30 Day Avg. Volume13,579,920
Standard Deviation0.29
R-Squared0.13
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

9.91%2.44%2.97%84.68%
2.97% Other Institutional Investors
84.68% Public Companies and
Individual Investors

IMU FAQ

What was Imugene Limited’s price range in the past 12 months?
Imugene Limited lowest share price was AU$0.04 and its highest was AU$0.15 in the past 12 months.
    What is Imugene Limited’s market cap?
    Currently, no data Available
    When is Imugene Limited’s upcoming earnings report date?
    Imugene Limited’s upcoming earnings report date is Aug 30, 2024 which is in 154 days.
      How were Imugene Limited’s earnings last quarter?
      Imugene Limited released its earnings results on Feb 28, 2024. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.01.
        Is Imugene Limited overvalued?
        According to Wall Street analysts Imugene Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Imugene Limited pay dividends?
          Imugene Limited does not currently pay dividends.
          What is Imugene Limited’s EPS estimate?
          Imugene Limited’s EPS estimate is -AU$0.01.
            How many shares outstanding does Imugene Limited have?
            Imugene Limited has 7,318,369,600 shares outstanding.
              What happened to Imugene Limited’s price movement after its last earnings report?
              Imugene Limited reported an EPS of -AU$0.01 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Imugene Limited?
                Currently, no hedge funds are holding shares in AU:IMU
                ---

                Imugene Limited Stock Smart Score

                6
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Imugene Limited

                Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Immutep
                Immunome
                Imugene Limited
                Immuron
                ImmunoCellular Therapeutics
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis